Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Direct efficiency of different modes of scheme “paclitaxel Caelyx” in the treatment of patients having inflammatory breast cancer

Suriya Yessentayeva, Nino Chichua, A. Khozhayev, Zhanna Mussakhanova, Ramil Abdrakhmanov, Bakir Kozhakhmetov, Gulnar Tleugabilova, Roza Abdulakhanova, Yu. Starchenko, K. Niyazbekova

. 2011 ; 8 (4) : 9-15.

Jazyk angličtina Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc14048737

Inflammatory breast cancer (IBC) with a poor prognosis occurs in 1-5% of patients with breast cancer. Combination of Paclitaxel and Caelyx were applied for 42 patients with IBC with the use of 2 regimens. Paclitaxel - 135 mg/m² 1 day, Caelyx 40 mg/m² 1day within a cycle of 3 weeks (21 sick women); the weekly regimen has a scheme: 60 mg/m² on 1st, 8th and15th days and Caelyx - 25 mg/m² on 1st, 8th days within a cycle of 4 weeks (21 sick women). The final analysis of the effectiveness of 2 chemotherapy regimens showed that an objective impact was reached in 85.7% (18/21) in the group of weekly insertion of the drugs by the end of the research; and in the group of routine chemotherapy it was 52.4% (11/21). Though general results are satisfactory in both 2 regimens of the chemotherapy, the weekly insertion of the drugs let to decrease a hematologic toxicity of 3-4 degree in 2.5-3 times and a frequency of LPS in 10 times.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc14048737
003      
CZ-PrNML
005      
20141204144404.0
007      
ta
008      
140311s2011 xr f 000 0eng||
009      
eAR
024    7_
$a 10.15208/mhsj.2011.152 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xr
100    1_
$a Suriya Yessentayeva, $u Kazakh Research Institute of Oncology and Radiology, Almaty State Medical Refresher Institute, Kazakh National Medical University
245    10
$a Direct efficiency of different modes of scheme “paclitaxel Caelyx” in the treatment of patients having inflammatory breast cancer / $c Suriya Yessentayeva, Nino Chichua, A. Khozhayev, Zhanna Mussakhanova, Ramil Abdrakhmanov, Bakir Kozhakhmetov, Gulnar Tleugabilova, Roza Abdulakhanova, Yu. Starchenko, K. Niyazbekova
504    __
$a Literatura
520    9_
$a Inflammatory breast cancer (IBC) with a poor prognosis occurs in 1-5% of patients with breast cancer. Combination of Paclitaxel and Caelyx were applied for 42 patients with IBC with the use of 2 regimens. Paclitaxel - 135 mg/m² 1 day, Caelyx 40 mg/m² 1day within a cycle of 3 weeks (21 sick women); the weekly regimen has a scheme: 60 mg/m² on 1st, 8th and15th days and Caelyx - 25 mg/m² on 1st, 8th days within a cycle of 4 weeks (21 sick women). The final analysis of the effectiveness of 2 chemotherapy regimens showed that an objective impact was reached in 85.7% (18/21) in the group of weekly insertion of the drugs by the end of the research; and in the group of routine chemotherapy it was 52.4% (11/21). Though general results are satisfactory in both 2 regimens of the chemotherapy, the weekly insertion of the drugs let to decrease a hematologic toxicity of 3-4 degree in 2.5-3 times and a frequency of LPS in 10 times.
650    12
$a nádory prsu $x farmaterapie $7 D001943
650    _2
$a prognóza $7 D011379
650    _2
$a výsledek terapie $7 D016896
650    12
$a antitumorózní látky fytogenní $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000972
650    _2
$a doxorubicin $x analogy a deriváty $x farmakologie $7 D004317
650    12
$a antibiotika antitumorózní $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000903
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
700    1_
$a Nino Chichua, $u Kazakh Research Institute of Oncology and Radiology, Almaty State Medical Refresher Institute, Kazakh National Medical University
700    1_
$a Khozhayev, A. $u Kazakh Research Institute of Oncology and Radiology, Almaty State Medical Refresher Institute, Kazakh National Medical University $7 gn_A_00000019
700    1_
$a Zhanna Mussakhanova, $u Kazakh Research Institute of Oncology and Radiology, Almaty State Medical Refresher Institute, Kazakh National Medical University
700    1_
$a Ramil Abdrakhmanov, $u Kazakh Research Institute of Oncology and Radiology, Almaty State Medical Refresher Institute, Kazakh National Medical University
700    1_
$a Bakir Kozhakhmetov, $u Kazakh Research Institute of Oncology and Radiology, Almaty State Medical Refresher Institute, Kazakh National Medical University
700    1_
$a Gulnar Tleugabilova, $u Kazakh Research Institute of Oncology and Radiology, Almaty State Medical Refresher Institute, Kazakh National Medical University
700    1_
$a Roza Abdulakhanova, $u Kazakh Research Institute of Oncology and Radiology, Almaty State Medical Refresher Institute, Kazakh National Medical University
700    1_
$a Yu. Starchenko, $u Kazakh Research Institute of Oncology and Radiology, Almaty State Medical Refresher Institute, Kazakh National Medical University
700    1_
$a K. Niyazbekova $u Kazakh Research Institute of Oncology and Radiology, Almaty State Medical Refresher Institute, Kazakh National Medical University
773    0_
$t Medical and health science journal $x 1804-1884 $g Roč. 8, č. 4 (2011), s. 9-15 $w MED00177704
856    41
$u http://academicpublishingplatforms.com/journal.php?journal=MHSJ $y domovská stránka časopisu - plný text volně přístupný
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20140306080010 $b ABA008
991    __
$a 20141204144359 $b ABA008
999    __
$a ok $b bmc $g 1015765 $s 847294
BAS    __
$a 3 $a 4
BMC    __
$a 2011 $b 8 $c 4 $d 9-15 $i 1804-1884 $m Medical and Health Science Journal $n Med. Health Sci. J. $x MED00177704
LZP    __
$c NLK183 $d 20141204 $a NLK 2014-17/vt

Najít záznam

Citační ukazatele

Možnosti archivace